On a global level, the alarming prevalence of chronic cough amongst individuals has propelled healthcare companies in the cough hypersensitivity syndrome treatment market to develop efficacious treatment options. As such, they are increasing their focus on developing improved formulations of antitussive agents. This trend is distinctly true, since antitussive agents are projected to dominate the cough hypersensitivity syndrome treatment market, with an estimated revenue of ~US$ 2.8 billion by 2027.
In order to relieve patients from cough hypersensitivity, healthcare companies are investing in opiates and GABA (gamma-aminobutyric acid)-related compounds. Opiates serve as effective cough suppressants and possess efficacious antitussive properties to treat chronic intractable cough. Likewise, companies are increasing their production capabilities of tramadol, an opioid medication that is similar to the molecular formula of codeine drugs.
Since chronic cough causes increased body pain, companies in the cough hypersensitivity syndrome treatment market are increasing the availability of babapentin and pregabalin, which are GABA-related compounds, and act as neuromodulators for the treatment of neuropathic pain and epilepsy. It has been found in placebo-controlled trials that, gabapentin is well-tolerated for the treatment of refractory chronic cough.
Get a glimpse of the in-depth analysis through our Report Brochure
Healthcare companies in the cough hypersensitivity syndrome treatment space are increasing clinical trials to study the effects of aerosolized capsaicin with behavioral cough suppression. It has been found that, the inhalation of aerosolized capsaicin in gradually increasing doses has contributed to the decrease in cough sensitivity. Healthcare providers have recommended the repetition of the treatment sessions to effectively minimize the instances of cough hypersensitivity.
Chronic cough is associated with high prevalence of gastroesophageal reflux disease (GERD). Hence, companies in the cough hypersensitivity syndrome treatment market are innovating in proton pump inhibitors (PPI) therapy. Proton pump inhibitors currently account for the second-highest revenue share amongst the drugs in the cough hypersensitivity syndrome treatment market. PPI therapy is also effective for diseases related to GERD, such as achalasia, infectious esophagitis, and eosinophilic esophagitis. In order to treat asthma, healthcare providers in the cough hypersensitivity syndrome treatment market are increasing research capabilities in bronchodilators that include short acting beta-2 agonists. They also recommend patients to undergo spirometry to avoid the side effects of beta agonists.
To know the scope of our report Get a Sample on Cough Hypersensitivity Syndrome Treatment Market
The cough hypersensitivity syndrome treatment market is anticipated to grow at a modest CAGR of ~5%. However, the nature of the market is consolidated, which makes it challenging for emerging market players to enter into the bracket of prominent and leading healthcare companies. Although the market is consolidated, the inefficiency of drugs and their adverse effects are negatively affecting market growth.
For instance, voltage-gated sodium channels reduce excitability and sensory nerve activity amongst patients. However, there is a growing need for newer agents that present realistic options for cough hypersensitivity syndrome patients. In many cases, proton pump inhibitors lead to complications of refractory GERD, with recurrence of reflux symptoms. Hence, healthcare companies in the cough hypersensitivity syndrome treatment market should increase awareness about the judicious administration of PPIs. They should team up with healthcare providers who can encourage patients to undergo early upper endoscopy to evaluate new alarm symptoms.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
New clinical guidelines by health commissions across nations suggest the screening, diagnosis, and treatment of chronic cough at regular intervals. Healthcare companies in the cough hypersensitivity syndrome treatment market should increase their research capabilities to understand pathophysiology for refractory chronic cough.
Antitussive agents are being increasingly used by healthcare providers to treat various complications of cough hypersensitivity. However, certain agents provide no clinical evidence of improvement in the health of patients. As such, there is an increasing need for the optimized clinical evaluation of uncontrolled symptoms and mechanistic understanding of neurobiology to achieve promising therapeutic targets. Market players should introduce more treatment options in anti-inflammatory therapy for patients with cough-variant asthma and eosinophilic bronchitis.
Cough Hypersensitivity Syndrome Treatment Market Description
Cough Hypersensitivity Syndrome Treatment Market: Drivers
Cough Hypersensitivity Syndrome Treatment Market: Segment Analysis
Cough Hypersensitivity Syndrome Treatment Market: Major Players
Cough Hypersensitivity Syndrome Treatment Market – Segmentation
TMR’s study on the global cough hypersensitivity syndrome treatment market includes information divided into three sections: drug class, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these sections of the global cough hypersensitivity syndrome treatment market have been discussed in detail.
|
Drug Class |
|
|
Distribution Channel |
|
|
Region |
|
Cough hypersensitivity syndrome treatment market to reach ~US$ 11 Bn by the 2027
Cough hypersensitivity syndrome treatment market is projected to increase at a CAGR of 5.5% 2019 - 2027
Cough hypersensitivity syndrome treatment market is driven by rise in the prevalence of chronic respiratory diseases
North America dominated the global cough hypersensitivity syndrome treatment market, and is projected to continue its dominance during the forecast period.
Key players in the cough hypersensitivity syndrome treatment market include Pfizer, Inc., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca, F. Hoffmann-La Roche Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Cough Hypersensitivity Syndrome Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Respiratory Drug Classes Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Epidemiology Cough hypersensitivity syndrome
5.2. Pipeline Analysis
6. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Drug Class, 2017–2027
6.3.1. Antitussive Agents
6.3.2. Inhaled Corticosteroids (ICS)
6.3.3. Short Acting Beta2-Agonists (SABA)
6.3.4. Anti-cholinergics
6.3.5. Antihistamines
6.3.6. Proton Pump Inhibitors
6.3.7. Others
6.4. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Drug Class
7. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel
8. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, By Region
8.1. Key Findings
8.2. Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Region
9. North America Cough Hypersensitivity Syndrome Treatment Market Value Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
9.2.1. Antitussive Agents
9.2.2. Inhaled Corticosteroids (ICS)
9.2.3. Short Acting Beta2-Agonists (SABA)
9.2.4. Anti-cholinergics
9.2.5. Antihistamines
9.2.6. Proton Pump Inhibitors
9.2.7. Others
9.3. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. North America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
10.2.1. Antitussive Agents
10.2.2. Inhaled corticosteroids (ICS)
10.2.3. Short-Acting Beta2-Agonists (SABA)
10.2.4. Anti-cholinergics
10.2.5. Antihistamines
10.2.6. Proton Pump Inhibitors
10.2.7. Others
10.3. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country
11. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
11.2.1. Antitussive Agents
11.2.2. Inhaled corticosteroids (ICS)
11.2.3. Short-Acting Beta2-Agonists (SABA)
11.2.4. Anti-cholinergics
11.2.5. Antihistamines
11.2.6. Proton Pump Inhibitors
11.2.7. Others
11.3. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
12.2.1. Antitussive Agents
12.2.2. Inhaled corticosteroids (ICS)
12.2.3. Short-Acting Beta2-Agonists (SABA)
12.2.4. Anti-cholinergics
12.2.5. Antihistamines
12.2.6. Proton Pump Inhibitors
12.2.7. Others
12.3. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Drug Class, 2017–2027
13.2.1. Antitussive Agents
13.2.2. Inhaled corticosteroids (ICS)
13.2.3. Short-Acting Beta2-Agonists (SABA)
13.2.4. Anti-cholinergics
13.2.5. Antihistamines
13.2.6. Proton Pump Inhibitors
13.2.7. Others
13.3. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast By Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis by Company (2018)
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. GlaxoSmithKline plc
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. Boehringer Ingelheim GmbH
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. Strategic Overview
14.3.3.5. SWOT Analysis
14.3.4. AstraZeneca
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. F. Hoffmann-La Roche Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. Strategic Overview
14.3.5.5. SWOT Analysis
14.3.6. Teva Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. Strategic Overview
14.3.6.5. SWOT Analysis
14.3.7. Novartis AG
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. Strategic Overview
14.3.7.5. SWOT Analysis
14.3.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. Strategic Overview
14.3.8.5. SWOT Analysis
14.3.9. Vertex Pharmaceuticals Incorporated
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. Strategic Overview
14.3.9.5. SWOT Analysis
14.3.10. Johnson & Johnson Consumer Inc.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. Strategic Overview
14.3.10.5. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis
Table 02: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 03: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 04: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 05: North America Cough Hypersensitivity Syndrome Treatment market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 06: North America Cough Hypersensitivity Syndrome Treatment market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 07: North America Cough Hypersensitivity Syndrome Treatment market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 08: Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 09: Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 10: Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 11: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 12: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 13: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 14: Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 16: Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 17: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 18: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 19: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
List of Figures
Figure 01: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2027
Figure 02: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027
Figure 03: Global Cough Hypersensitivity Syndrome Treatment Market Value Share (%), by Drug Class (2019)
Figure 04: Global Cough Hypersensitivity Syndrome Treatment Market Value Share (%), by Distribution Channel (2019)
Figure 05: Global Cough Hypersensitivity Syndrome Treatment Market Value Share (%), by Region (2019)
Figure 06: Porter’s Five Force Analysis– Cough Hypersensitivity Syndrome Treatment Market
Figure 07: Epidemiology of Cough Hypersensitivity Syndrome (Chronic Cough)
Figure 08: Global Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 09: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Antitussive Agents, 2017–2027
Figure 10: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Inhaled Corticosteroids, 2017–2027
Figure 11: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Short acting Beta-2 Agonists, 2017–2027
Figure 12: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Anticholinergics, 2017–2027
Figure 13: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Antihistamines, 2017–2027
Figure 14: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Proton Pump Inhibitors, 2017–2027
Figure 15: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027
Figure 16: Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Drug Class, 2019?2027
Figure 17: Global Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 18: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Hospital Pharmacies, 2017–2027
Figure 19: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Retail Pharmacies, 2017–2027
Figure 20: Global Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, by Online Pharmacies, 2017–2027
Figure 21: Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Distribution Channel, 2019?2027
Figure 22: Global Cough Hypersensitivity Syndrome Treatment Market: Regional Outlook
Figure 23: Global Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Region, 2018 and 2027
Figure 24: Global Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Region, 2019–2027
Figure 25: North America Cough Hypersensitivity Syndrome Treatment market Value (US$ Mn) Forecast, 2019–2027
Figure 26: North America Cough Hypersensitivity Syndrome Treatment market Value Share, by Country, 2018 and 2027
Figure 27: North America Cough Hypersensitivity Syndrome Treatment market Attractiveness, by Country, 2019–2027
Figure 28: North America Cough Hypersensitivity Syndrome Treatment market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 29: North America Cough Hypersensitivity Syndrome Treatment market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 30: North America Cough Hypersensitivity Syndrome Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 31: North America Cough Hypersensitivity Syndrome Treatment market Attractiveness, by Distribution Channel, 2019–2027
Figure 32: Europe Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, 2019–2027
Figure 33: Europe Cough Hypersensitivity Syndrome Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 34: Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 36: Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 35: Europe Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 37: Europe Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 38: Europe Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 39: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, 2019–2027
Figure 40: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 41: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 42: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 43: Asia Pacific Cough Hypersensitivity Syndrome Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 44: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 45: Asia Pacific Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 46: Latin America Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, 2019–2027
Figure 47: Latin America Cough Hypersensitivity Syndrome Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 48: Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 49: Latin America Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 50: Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 51: Latin America Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 52: Latin America Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 53: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value (US$ Mn) Forecast, 2019–2027
Figure 54: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 55: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 56: Middle East & Africa Cough Hypersensitivity Syndrome Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 57: Middle East & Africa Cough Hypersensitivity Syndrome Market Attractiveness Analysis, by Drug Class, 2019?2027
Figure 58: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 59: Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 60: Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 61: Pfizer, Inc. Breakdown of Net Sales (%), by Region, 2018
Figure 62: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 63: Pfizer, Inc. Breakdown of Net Sales (%), by Business Segment, 2018
Figure 64: GSK R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 65: GSK Breakdown of Net Sales (%), by Geography, 2018
Figure 66: GSK Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 67: GSK Breakdown of Net Sales (%), by Business Segment, 2018
Figure 68: Boehringer Ingelheim GmbH R&D Expenditure (US$ Mn), 2016–2018
Figure 69: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (Company Level), 2018
Figure 70: Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018
Figure 71: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Business Segment, 2018
Figure 72: AstraZeneca Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 73: AstraZeneca Breakdown of Net Sales (%), by Region/Country, 2018
Figure 74: AstraZeneca R&D Expenses (US$ Mn), 2015–2018
Figure 75: AstraZeneca Breakdown of Net Sales (%), by Business Segment, 2018
Figure 76: F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018
Figure 77: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Business Segment, 2018
Figure 78: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Region, 2018
Figure 79: F. Hoffmann-La Roche Ltd. Research & Development Cost (US$ Mn), 2015–2017
Figure 80: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 81: Teva Pharmaceutical Industries Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 82: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018
Figure 83: Novartis AG Breakdown of Net Sales, by Region, 2018
Figure 84: Novartis AG R&D Intensity and Sales & Marketing Intensity - Company Level, 2017–2018
Figure 85: Novartis AG Breakdown of Net Sales, by Business Segment, 2018
Figure 86: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 87: Merck & Co., Inc. Revenue Breakdown of Net Sales (%), by Segment, 2018
Figure 88: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2018
Figure 89: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 90: Vertex Pharmaceuticals Incorporated Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 91: Vertex Pharmaceuticals Incorporated Breakdown of Net Sales (%), by Region/Country, 2018
Figure 92: Vertex Pharmaceuticals Incorporated R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 93: Johnson & Johnson Consumer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 94: Johnson & Johnson Consumer Inc. Breakdown of Net Sales (%), by Region, 2018
Figure 95: Johnson & Johnson Consumer Inc. Breakdown of Net Sales (%), by Business Segment, 2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cough Hypersensitivity Syndrome Treatment Market
*86 figures and 60 tables includes